Clinical Trials Logo
  1. Home
  2. Crohn's Disease
  3. NCT01860846
  4. Details
NCT01860846 Clinical Trial

Improvement of Work Productivity and Quality of Life With Anti-Tumor Necrosis Factor (TNF) Therapies Used in Crohn's Disease in Routine Clinical Practice in Turkey

Crohn's Disease Clinical Trial

— IDEA  

Official title:
Improvement of Work Productivity and Quality of Life With Anti-TNF Therapies Used in Crohn's Disease in Routine Clinical Practice in Turkey

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01860846
Other study ID # P13-338
Secondary ID
Status Completed
Phase N/A
First received May 21, 2013
Last updated February 17, 2016
Start date May 2013
Est. completion date February 2016

Study information
Verified date February 2016
Source AbbVie
Contact n/a
Is FDA regulated No
Health authority Turkey: Ethics CommitteeTurkey: Ministry of Health
Study type Observational

Clinical Trial Summary

This post marketing observational study (PMOS) is designed to collect long-term data on the work productivity and changes in quality of life measurements with anti-Tumor Necrosis Factor therapies in patients with moderate to severe Crohn's disease whom are intolerant or/and unresponsive to conventional therapy.

Recruitment information / eligibility
Status Completed
Enrollment 104
Est. completion date February 2016
Est. primary completion date February 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Male or female patients between 18-65 years of age with moderately/severely (Crohn's Disease Activity Index 220-450) active Crohn's disease with/without fistula formation

- Patients who are able to provide authorization to use and disclose information related with the study

- Proven diagnosis of Crohn's Disease in accordance with international diagnostic criteria such as European Crohn's and Colitis Organisation (ECCO) guidelines

- Patients for whom the physician has initiated Crohn's disease treatment with anti-Tumor Necrosis Factors in accordance with Turkish Ministry of Health regulations and reimbursements.

Exclusion Criteria:

- Subject has a history of any kind of biological therapy and/or anti-Tumor Necrosis Factor treatments for Crohn's disease or other indications

- Subject has septic complications (active infection and/or active Tuberculosis, undrained abscess)

- Patients who have bowel obstructions and fibrotic strictures

- Subject has received any investigational drug within 30 days prior to the Visit 1 at baseline

- For any reason, subject is considered by the investigator to be an unsuitable.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Turkey Site Reference ID/Investigator# 62756 Ankara
Turkey Site Reference ID/Investigator# 67902 Ankara
Turkey Site Reference ID/Investigator# 67904 Ankara
Turkey Site Reference ID/Investigator# 67909 Bornova, Izmir
Turkey Site Reference ID/Investigator# 67905 Edirne
Turkey Site Reference ID/Investigator# 67907 Istanbul
Turkey Site Reference ID/Investigator# 67912 Istanbul
Turkey Site Reference ID/Investigator# 67915 Istanbul
Turkey Site Reference ID/Investigator# 93553 Istanbul
Turkey Site Reference ID/Investigator# 67913 Izmir
Turkey Site Reference ID/Investigator# 67914 Izmir
Turkey Site Reference ID/Investigator# 93554 Kocaeli
Turkey Site Reference ID/Investigator# 94495 Konya
Turkey Site Reference ID/Investigator# 67910 Mersin
Turkey Site Reference ID/Investigator# 67906 Sihhiye Ankara

Sponsors (1)
Lead Sponsor Collaborator
AbbVie

Country where clinical trial is conducted

Turkey, 

Outcome
Type Measure Description Time frame Safety issue
Primary Evaluation of Work Absenteeism To collect the number of missed working days and the number of working days 12 months No
Primary Total Work Productivity Impairment (TWPI) To collect Total Work Productivity Impairment by Total Work Productivity Impairment Scale 12 months No
Primary Total Activity Impairment (TAI) scales To collect Total Activity Impairment by Total Activity Impairment Scale 12 months No
Secondary Average Short Form Health Survey-36 (SF-36) score change Day 0 to 12 months No
Secondary Average Inflammatory Bowel Disease Questionnaire (IBDQ) score change Day 0 to 12 months No
Secondary Number of Subjects with Serious Adverse Events 12 months Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03815851 - Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery N/A
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Completed NCT02883452 - A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis Phase 1
Recruiting NCT04777656 - Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. Phase 3
Terminated NCT03017014 - A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
Recruiting NCT06053424 - Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease Phase 1
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Not yet recruiting NCT02858557 - The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases N/A
Terminated NCT02882841 - MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients N/A
Terminated NCT02417974 - Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT) Phase 2
Completed NCT03010787 - A First Time in Human Study in Healthy Volunteers and Patients Phase 1
Completed NCT02542917 - Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
Active, not recruiting NCT02316678 - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics N/A
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02265588 - Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD). N/A
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Completed NCT02193048 - Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
Recruiting NCT02395354 - Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease N/A
Completed NCT01951326 - Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease Phase 3

External Links